1 Min Read
July 5 (Reuters) - ProQR Therapeutics Nv
* ProQR’s drug candidate QRX-411 for usher syndrome receives orphan drug designation from FDA and EMA Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.